In a latest press release issued by the Federal agency United States Food and Drug Administration the agency had expanded the approved use of blood thinning drug Xarelto (rivaroxaban) to include treating pulmonary embolism (PE), deep vein thrombosis (DVT) or and to reduce the risk of recurrent DVT and PE following initial treatment. According to reports from the U.S.F.D.A a total of 9,478 patients were recruited in the 3 different clinical trials that were conducted to assess and determine the efficacy and safety of the drug for new indications. In all the subjects patients with PE or DVT were randomly assigned to receive Xarelto, combination of enoxaparin or a placebo.

Previous ArticleDiagnosis And Treatment Of Head And Neck Cancer Next ArticleReport Says FDA Safety Update On Pradaxa Insufficient
Verdicts and Settlements
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers